Following at this time’s assertion by the European Medicines Company (EMA) concerning the COVID-19 vaccine Vaxzevria (previously AstraZeneca), EU Well being Ministers met by videoconference at this time, Wednesday 7 April, to debate a typical method to the long run roll-out of Vaxzevria vaccine. On this event, Minister Romain Schneider changed Well being Minister Paulette Lenert.
Romain Schneider identified that it’s essential that EU Member States have the means to take knowledgeable choices on easy methods to deploy their vaccination technique in the absolute best curiosity of residents’ public well being. “Our objective stays to vaccinate as many individuals as potential as rapidly as potential, primarily based on sound scientific proof in regards to the efficacy and security of obtainable vaccines.” acknowledged Romain Schneider.
Though the EMA discovered a potential hyperlink between very uncommon instances of surprising blood clots and the administration of the AstraZeneca vaccine, it additionally notes that “The advantages of the AstraZeneca vaccine, by way of prevention of COVID-19 an infection, proceed to far outweigh the dangers and the general public ought to proceed to take the vaccine when invited to take action.” The EMA evaluation, primarily based on knowledge from vaccinated people between 18 and 79 years of age, didn’t reveal any distinction between women and men, nor did it verify, primarily based on presently out there knowledge, the existence of particular danger elements.
Based mostly on this scientific evaluation by the European Company, Luxembourg has determined to proceed to manage the AstraZeneca vaccine with out distinction of age and gender.
In at this time’s assertion, the EMA reminds healthcare professionals and recipients of the vaccine to contemplate the potential of very uncommon instances of blood clots occurring inside two weeks of vaccination.
Sufferers ought to search instant medical recommendation in the event that they expertise the next signs:
- shortness of breath
- chest ache
- swelling of the legs
- persistent belly (stomach) ache
- neurological signs, together with extreme and protracted complications or blurred imaginative and prescient
- small spots of blood below the pores and skin past the injection web site
Vaxzevria is considered one of 4 vaccines authorised within the EU to forestall COVID-19. Research present that it’s efficient in stopping the illness. It additionally reduces the chance of hospitalisation and loss of life associated to COVID-19.
The EMA has dedicated to proceed its detailed evaluation over the approaching months, to maintain monitoring the protection and efficacy of the vaccine and to offer the general public with the most recent data out there.
Press launch by the Ministry of State / Ministry of Well being